Physician profile
Matthew D Fenlason
NPI 1790148039
$2,088.86
in general payments reported to CMS, 2019-2025
23 companies · $638 in 2025
The $638 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.10 · 2020: $11.94 · 2022: $27.90 · 2023: $643 · 2024: $729 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.02 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.80 | 2022-2025 | |
| Pfizer INC. | $294.88 | 2023-2025 | |
| Amgen INC. | $188.14 | 2023-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $181.21 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $168.96 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Insightec,INC | $131.69 | 2023-2024 | Exablate |
| Astrazeneca Pharmaceuticals Lp | $124.38 | 2020-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $120.08 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Alnylam Pharmaceuticals INC. | $96.83 | 2023 | Givlaari |
| Philips North America LLC | $96.60 | 2024 | (Ck6) Holter |
| Janssen Pharmaceuticals, INC | $58.10 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.27 | 2024-2025 | Jardiance |
| Inspire Medical Systems, INC. | $39.79 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $33.83 | 2025 | Ajovy |
| Sumitomo Pharma America, INC. | $24.60 | 2023 | Gemtesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.58 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $20.30 | 2025 | Opsynvi |
| Exact Sciences Corporation | $16.63 | 2025 | The Cologuard Plus Collection Kit |
| Leo Pharma INC. | $16.52 | 2019 | |
| Biogen, INC. | $16.42 | 2024 | Spinraza |
| Novartis Pharmaceuticals Corporation | $14.79 | 2024 | |
| Abbott Laboratories | $13.81 | 2022 | |
| Snap Diagnostics LLC | $11.65 | 2023 | Snap Diagnostics Study |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Fenlason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.